Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Medical Therapy Estimated by FDG PET/CT in Myocardial Sarcoidosis (OMT-CS)
jRCTs041180111Completed
- Sponsor
- Grants-in-Aid for Scientific Research
- Start
- Dec 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisone and methotrexate in cardiac sarcoidosis (CS) (3 arms), sponsored by Grants-in-Aid for Scientific Research. Primary endpoint: Decreasing rate of TLG by prednisone therapy for 12 (18) months. Started Dec 2016; status: completed.
02
Drugs
prednisonemethotrexate
03
Conditions
cardiac sarcoidosis (CS)
Beyond the preview
Go deeper on jRCTs041180111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041180111.